GE / EN / RU

Non-invasive prenatal test Panorama: For patients


Panorama Test

Panorama prenatal test— the most comprehensive and accurate non-invasive prenatal screening test among those available at the time of the original publication. It estimates the individual risk of having a baby with chromosomal abnormalities. The method was developed through research by the American company Natera, which specializes in reproductive technologies and prenatal diagnosis. This technique began being used in the United States in 2012.

The principal difference from invasive diagnostic methods (amniocentesis, cordocentesis and chorionic villus sampling) is that no invasive procedure is required.

Only maternal venous blood is required for the analysis, so no manipulations are performed that could cause the pregnancy to end. Fetal DNA is isolated and analysed from the mother’s blood, making it possible to obtain more reliable results than with conventional biochemical screening.

Blood for Panorama testing can be collected from nine weeks of pregnancy.

The collected blood sample is separated into layers using a centrifuge. A special technique, sequencing, is then used to process genetic information from the mother and the fetus. Sequencing data are analysed by Natera's proprietary algorithm, NATUS, which helps distinguish maternal and fetal DNA. The fetal DNA information is subjected to computer analysis, and the results are used to calculate an individual risk level for chromosomal abnormalities.

Turnaround time: approximately two weeks from blood collection to receiving the test results.

Conditions screened by non-invasive testing

The test examines chromosomes. A typical human cell contains 46 chromosomes arranged in 23 pairs.

An extra chromosome in a pair is called a trisomy; the absence of one chromosome is called a monosomy.

The non-invasive prenatal Panorama test makes it possible to determine the degree of risk of conditions such as:

  • Down syndrome — trisomy 21 (significant intellectual and physical developmental impairments, short stature and reduced life expectancy).
  • Edwards syndrome — trisomy 18 (severe intellectual disability, congenital malformations of the heart, brain and kidneys, skeletal abnormalities, cleft palate and cleft lip).
  • Patau syndrome — trisomy 13 (intellectual disability; cleft lip and palate; abnormalities of the development of the brain and spinal cord, heart and genital organs; and extra fingers or toes).
  • Triple X syndrome — girls with an additional X chromosome. They may experience difficulties with learning and socialisation during their lives.
  • Klinefelter syndrome (47,XXY) — a sex-chromosome condition affecting males, sometimes associated with learning difficulties and reduced fertility.
  • Triple X syndrome (47,XXX) — an additional X chromosome in females; some affected individuals experience learning or developmental difficulties.
  • Turner syndrome (45,X) — complete or partial absence of an X chromosome in females, potentially associated with short stature, heart abnormalities and infertility.

Indications for Panorama testing in early pregnancy

Non-invasive prenatal DNA testing with Panorama may be considered in the following situations:

  • Increased risk identified by ultrasound or biochemical screening.
  • Maternal age 35 years or older or paternal age 40 years or older.
  • A family history of hereditary disorders or a child with a chromosomal condition.
  • A diagnosed chromosomal disorder in either parent.
  • A history of pregnancy loss, stillbirth or infertility.
  • Illness during pregnancy.
  • Use of IVF. Since fetal aneuploidies can also occur in people who do not belong to risk groups, we recommend that all pregnant women consider NIPT to gain reassurance about their baby’s health. Testing can also be performed in twin pregnancies!

Limitations of Panorama testing

Panorama is a non-invasive screening method for selected chromosomal conditions. Test eligibility depends on pregnancy characteristics and medical history; consult your healthcare professional.

  • Pregnancies with three or more fetuses;
  • Pregnancy before nine weeks;
  • Surrogacy (eligibility should be confirmed individually).

Benefits of Panorama NIPT

Screening from early pregnancy

From 9 weeks of pregnancy

Non-invasive for mother and fetus

- Routine venous blood draw

- A trained healthcare professional collects the sample

Convenient access from different cities

Ask our consultant about collection kits

Fast

10–14 working days

Accuracy: 99%

- Low false-positive rate

- SNP-based method distinguishes maternal and placental DNA

Fetal fraction (placental DNA proportion)

- Analysis considers maternal and placental DNA

- A sufficient fetal fraction is required for a result

Have a question?

Let us discuss it. Complete the form and our specialist will answer your questions.

We serve patients across Georgia!

Send an enquiry
Get in touchMessage on WhatsApp

Please do not send medical information or test results through this form.